2023
Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor J, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal M, Marianayagam N, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera S, Omay S, Mishra-Gorur K, McGuone D, Morales-Valero S, Fulbright R, Gunel M, Erson-Omay E, Moliterno J. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. Journal Of Neurosurgery 2023, 139: 1648-1656. PMID: 37243548, DOI: 10.3171/2023.4.jns222929.Peer-Reviewed Original ResearchConceptsSubtotal resectionSupratentorial tumorsElevated Ki-67High-risk featuresProgression-free survivalChromosome 1p deletionInfratentorial counterpartsInfratentorial tumorsPostoperative managementSomatic driver mutationsCerebral convexityGrade IIInfratentorial meningiomasKi-67Posterior fossaLoss of heterozygosityMeningiomasResectionTumorsWhole-exome sequencing dataDriver mutationsHigh gradeSignificant differencesExome sequencing dataSporadic meningiomas
2016
MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS
Chen H, Thomas C, Munoz F, Alexandrescu S, Horbinski C, Olar A, McGuone D, Camelo-Piragua S, Wang L, Pentsova E, Phillips J, Aldape K, Iafrate A, Golfinos J, Chi A, Zagzag D, Rosenblum M, Ohman-Strickland P, Hameed M, Snuderl M. MPTH-34. THE PROGNOSTIC VALUE OF POLYSOMY IN OLIGODENDROGLIAL TUMORS. Neuro-Oncology 2016, 18: vi113-vi113. DOI: 10.1093/neuonc/now212.471.Peer-Reviewed Original ResearchProgression-free survivalOverall survivalOligodendroglial tumorsBetter progression-free survivalShorter progression-free survivalGroup of patientsSignificant differencesCommon molecular testsFree survivalFavorable prognosisEarly recurrenceShorter survivalPrognostic significancePrognostic valueAnaplastic oligodendrogliomaBrain tumorsTumorsEntire groupMolecular testsCytogenetic patternDeletion statusHallmark featureSurvivalPatientsPolysomy